• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Kewaunee Scientific Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    1/15/25 8:22:49 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    8-K/A
    KEWAUNEE SCIENTIFIC CORP /DE/ 0000055529 0000055529 2024-11-01 2024-11-01

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K/A

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 1, 2024

     

     

    Kewaunee Scientific Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   0-5286   38-0715562

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS. Employer

    Identification No.)

     

    2700 West Front Street

    Statesville, North Carolina

      28677
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: 704-873-7202

     

     

    N/A

    (Former name or former address, if changed since last report.)

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $2.50 par value   KEQU   The Nasdaq Global Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    EXPLANATORY NOTE

    On November 1, 2024 (the “Closing Date”), Kewaunee Scientific Corporation, a Delaware corporation (the “Company”), announced the closing of the Company’s acquisition (the “Acquisition”) of Nu Aire, Inc., a Minnesota corporation (“Nu Aire”), pursuant to the Securities Purchase Agreement (the “Purchase Agreement”), dated as of the Closing Date, by and among the Company, Nu Aire, Richard A. Peters, William F. Peters, Rita Peters Revocable Trust, and any amendments thereto (“Rita Trust”), Richard A. Peters Irrevocable Trust dated May 18, 2020, and any amendments thereto (“R. Peters 2020 Trust”), Richard A. Peters Revocable Trust, and any amendments thereto (“R. Peters 2005 Trust”), Karan A. Peters Revocable Trust, and any amendments thereto (“K. Peters Trust”), William F. Peters 2023 Irrevocable Trust dated December 20, 2023, and any amendments thereto (“W. Peters 2023 Trust”), and William F. Peters Revocable Trust, and any amendments thereto (“W. Peters Trust” and, together with Richard A. Peters, William F. Peters, Rita Trust, R. Peters 2020 Trust, R. Peters 2005 Trust, K. Peters Trust, and W. Peters 2023 Trust, the “Sellers” and each, a “Seller”), and William F. Peters, as Sellers’ Representative.

    Pursuant to the terms of the Purchase Agreement, the Company purchased all of the outstanding capital stock of Nu Aire from the Sellers for $55,000,000 in the aggregate, subject to certain customary adjustments for debt, cash, transaction expenses and net working capital, as further described in the Purchase Agreement.

    Concurrently with the entry into the Purchase Agreement, on the Closing Date, the Company entered into a Loan Agreement (the “Loan Agreement”) with PNC Bank, National Association (“PNC”). The loans governed by the Loan Agreement include:

     

      •  

    a $20,000,000 committed senior secured revolving line of credit facility (the “Revolving Credit Facility”), which contains an option to increase the facility upon request by the Company and approval by PNC, in its discretion, by an additional $10,000,000; and

     

      •  

    a $15,000,000 term loan (the “Term Loan”).

    Additionally, on the Closing Date, the Company entered into subordinated seller notes (the “Seller Notes”) in an aggregate amount of $23,000,000. The Seller Notes accrue interest at 8% per annum, and will mature on the third (3rd) anniversary of the Closing Date, at which time the outstanding principal amount and all unpaid accrued interest will become due and payable by the Company. The Revolving Credit Facility, the Term Loan, and the Seller Notes are collectively referred to herein as the “Financing.”

    On the Closing Date, the Company filed a Current Report on Form 8-K (the “Initial 8-K”) to report the closing of the Acquisition and the Financing on such date. Under Item 9.01 of the Initial 8-K, in reliance on the instructions to such Item, the Company stated that (a) the Company would file the financial statements required by Item 9.01(a) of Form 8-K by an amendment to the Initial 8-K no later than 71 days from the date on which the Initial 8-K was required to be filed, and (b) the Company would file the financial statements required by Item 9.01 (b) of Form 8-K by an amendment to the Initial 8-K no later than 71 days from the date on which the Initial 8-K was required to be filed. Accordingly, this Current Report on Form 8-K/A (this “Amendment”) amends the Initial 8-K to provide the requisite historical audited financial statements of Nu Aire and the requisite pro forma financial information.

    The unaudited pro forma condensed combined financial information included in this Amendment are presented for illustrative purposes only, contain a variety of adjustments, assumptions and estimates, and are not necessarily indicative of what the combined Company’s actual financial position or results of operations would have been had the Acquisition and the Financing been completed on the date indicated. The combined Company’s actual results and financial position may differ materially and adversely from the unaudited pro forma condensed combined financial information included in this Amendment. Important factors that may affect actual results include, but are not limited to, risks and uncertainties relating to the Company’s or Nu Aire’s business, as applicable (including each company’s ability to achieve strategic goals, objectives, and targets over applicable periods), industry performance, and general business and economic conditions.


    Item 9.01

    Financial Statements and Exhibits.

    (a) Financial statements of businesses acquired.

    The audited financial statements of Nu Aire as of and for the fiscal year ended September 30, 2024, including the related notes thereto, are filed herewith as Exhibit 99.1.

    (b) Pro forma financial information.

    The unaudited pro forma condensed combined balance sheet of the Company as of October 31, 2024, and the unaudited pro forma condensed combined statements of operations of the Company for the year ended April 30, 2024 and the six months ended October 31, 2024, including the related notes thereto, giving effect to the Acquisition and the Financing, are filed herewith as Exhibit 99.2. The unaudited pro forma financial information gives effect to the Acquisition and the Financing on the basis of, and subject to, the assumptions set forth in accordance with Article 11 of Regulation S-X.

     

      (d)

    Exhibits:

     

    Exhibit
    No.
        
    23.1    Consent of Forvis Mazars, LLP
    99.1    Audited financial statements of Nu Aire, Inc. as of and for the fiscal year ended September 30, 2024, including the related notes thereto.
    99.2    Unaudited pro forma condensed combined balance sheet of the Company as of October 31, 2024, and the unaudited pro forma condensed combined statements of operations of the Company for the year ended April 30, 2024 and the six months ended October 31, 2024, including the related notes thereto.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    Signature

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

         

    (Registrant)

    Kewaunee Scientific Corporation

    Date: January 15, 2025      

    /s/ Donald T. Gardner III

          Donald T. Gardner III
         

    Vice President, Finance and

    Chief Financial Officer

    Get the next $KEQU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pyle Margaret B

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/27/26 10:11:07 AM ET
    $KEQU
    Medical Specialities
    Industrials

    President, CEO Hull Thomas David Iii sold $81,638 worth of shares (2,177 units at $37.50), decreasing direct ownership by 6% to 33,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/8/26 9:09:31 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Chief Financial Officer Gardner Donald T. Iii sold $75,140 worth of shares (2,000 units at $37.57), decreasing direct ownership by 17% to 9,564 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/7/26 3:59:57 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    SEC Filings

    View All

    SEC Form 10-Q filed by Kewaunee Scientific Corporation

    10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    3/13/26 11:31:23 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    3/11/26 4:05:04 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    2/25/26 4:06:39 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026

    STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2026. Fiscal Year 2026 Third Quarter Results:Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITD

    3/11/26 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich

    STATESVILLE, N.C., March 3, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company will attend the 2026 analytica tradeshow and conference, taking place in Munich from March 24-27. Kewaunee will be joined by the Company's recently acquired subsidiary, Nu Aire, Inc. (NuAire), a proven leader in containment and biosafety technologies. Together, they will showcase a complete and complementary portfolio of laboratory infrastructure and safety-focused solutions designed to support the needs of modern lab environments worldwide.Established

    3/3/26 4:01:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2026

    STATESVILLE, N.C., Feb. 25, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2026 financial results on Wednesday, March 11, 2026 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products

    2/25/26 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    4/7/25 10:57:11 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/24/25 4:32:54 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/18/25 3:20:26 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Leadership Updates

    Live Leadership Updates

    View All

    Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors

    STATESVILLE, N.C., Sept. 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announces the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Campbell brings decades of experience guiding organizations through significant growth and transformation. Campbell's impressive career spans leadership roles at global companies such as PepsiCo, Frito-Lay, and Griffin LLC, a DuPont venture. He also

    9/11/25 4:03:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    11/1/24 9:14:13 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 11:44:29 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 9:59:14 AM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Financials

    Live finance-specific insights

    View All

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025. Fiscal Year 2025 Fourth Quarter Results Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prio

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials